Heidi Hagen

Heidi Hagen is a member of Obsidian’s Board of Directors. Ms. Hagen has extensive experience in operations management and commercializing innovative technologies, including 20 years in the cell and gene therapy industry. Currently, Ms. Hagen is the Chief Technical Officer of Sonoma Biotherapeutics, a privately-held company leading the development of adoptive Treg cell therapies for autoimmune and inflammatory diseases. She also serves on the Board of Directors for the cell therapy company Vericel. Most recently, she served as interim CEO and sat on the board for Ziopharm Oncology, Inc., a publicly traded company developing immune-oncology gene and cell therapies. She is also a Co-Founder and former Chief Strategy Officer of Vineti, a software platform company for cell and gene therapy supply chain management. Formerly, she served as Global COO for SOTIO Biotech a.s. and the Senior Vice President of Operations for Dendreon. She began her career at Immunex Corporation and worked for ten years in a range of roles in drug development and operations management. Ms. Hagen has a B.S. in cell and molecular biology, an M.S. in bioengineering, and an MBA from the University of Washington.